Q-omics provides the consensus-scored FABP4 profile across patient tissues and cancer cell-line models. FABP4 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, FABP4 is differentially expressed in 13, with the highest sampling consensus in THCA. Additionally, FABP4 protein abundance shows 19,434 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight HNSC, THCA, and LSCC as cancer lineages where FABP4 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FABP4 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FABP4 survival associations across molecular data types. FABP4 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (4) and mass-spec protein abundance (8). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FABP4 RNA expression–survival associations across cancer types. High FABP4 expression shows unfavorable associations in HNSC, ACC and BLCA, but favorable associations in KIRC, UCEC and LIHC. The HNSC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .002). Together, the overview and detailed table identify HNSC as the clearest survival context for FABP4 RNA expression.
This table summarizes FABP4 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 6. The strongest signals are observed in THCA for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for FABP4. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FABP4 shows lower tumor expression in THCA, LUAD, KIRP, COAD and LUSC and higher tumor expression in LIHC. The THCA box plot shows higher FABP4 RNA expression in normal versus tumor tissue (log2 FC = −4.947, t-test p < 0.001).
This table shows molecular features associated with FABP4 in patient tissues and cancer cell lines. In patient samples, FABP4 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, FABP4 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BONE, while CRISPR and shRNA rows add functional-dependency signals in LIVER and URINARY_TRACT.
